Novan – $52 Million IPO

New York – October 14, 2016 – Cooley advised the underwriters on Novan’s $51.9 million initial public offering. The company now trades on The NASDAQ Global Market under the symbol “NOVN.”

Novan is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using its nitric oxide platform.

Piper Jaffray & Co. acted as sole book-running manager for the offering. JMP Securities and Wedbush PacGrow acted as co-managers for the offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta Partner, New York
Brent Siler Partner, Washington, DC
Alison Haggerty Associate, New York
Danielle Gershowitz Associate, New York
Natasha Leskovsek Partner, Washington, DC
Wendy Goldstein Partner, New York
Ivor Elrifi Partner, New York
Heidi A. Erlacher Partner in Charge - Boston
Renee Deming Retired Partner, Palo Alto
Darren DeStefano Partner, Reston
Phil Mitchell Partner, New York
Stephanie Gentile Partner, New York